Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “CytomX Therapeutics, Inc.”

62 pharma patents match "CytomX Therapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 62
Index total 30,257
Page 2 / 3

Quick answer

This filtered view shows 62 pharmaceutical patents matching "CytomX Therapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

62 results for “CytomX Therapeutics, Inc.” · 30,257 patents in full index Clear search

  1. US 11046759

    Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Jun 29, 2021 · Expires Jun 24, 2041

    granted
  2. US 11035859

    Compositions and methods for detecting protease activity in biological systems

    CytomX Therapeutics, Inc. · Granted Jun 15, 2021 · Expires Jun 10, 2041

    granted
  3. US 11028126

    Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  4. US 10875913

    Methods of treatment using activatable anti-EGFR antibodies

    CytomX Therapeutics, Inc. · Granted Dec 29, 2020 · Expires Dec 24, 2040

    granted
  5. US 10800850

    Therapeutic antibodies

    CytomX Therapeutics, Inc. · Granted Oct 13, 2020 · Expires Oct 8, 2040

    granted
  6. US 10745481

    Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Aug 18, 2020 · Expires Aug 13, 2040

    granted
  7. US 10709799

    Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Jul 14, 2020 · Expires Jul 9, 2040

    granted
  8. US 10669337

    Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same

    CytomX Therapeutics, Inc. · Granted Jun 2, 2020 · Expires May 28, 2040

    granted
  9. US 10669339

    Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Jun 2, 2020 · Expires May 28, 2040

    granted
  10. US 10611845

    Activatable antibodies that bind interleukin-6 receptor and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  11. US 10568977

    Antibodies that bind activatable antibodies and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Feb 25, 2020 · Expires Feb 20, 2040

    granted
  12. US 10533053

    Nucleic acids encoding activatable antibodies that bind epidermal growth factor receptor

    CytomX Therapeutics, Inc. · Granted Jan 14, 2020 · Expires Jan 9, 2040

    granted
  13. US 10513549

    Cleavage-activatable interferon-alpha proprotein

    CytomX Therapeutics, Inc. · Granted Dec 24, 2019 · Expires Dec 19, 2039

    granted
  14. US 10513558

    Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Dec 24, 2019 · Expires Dec 19, 2039

    granted
  15. US 10336824

    Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof

    CytomX Therapeutics, Inc. · Granted Jul 2, 2019 · Expires Jun 27, 2039

    granted
  16. US 10301380

    Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof

    CytomX Therapeutics, Inc. · Granted May 28, 2019 · Expires May 23, 2039

    granted
  17. US 10261083

    Compositions and methods for detecting protease activity in biological systems

    CytomX Therapeutics, Inc. · Granted Apr 16, 2019 · Expires Apr 11, 2039

    granted
  18. US 10233244

    Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Mar 19, 2019 · Expires Mar 14, 2039

    granted
  19. US 10179817

    Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Jan 15, 2019 · Expires Jan 10, 2039

    granted
  20. US 10138272

    Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Nov 27, 2018 · Expires Nov 22, 2038

    granted
  21. US 10118961

    Modified antibody containing the cleavable peptide with the amino acid sequence TGRGPSWV

    CytomX Therapeutics, Inc. · Granted Nov 6, 2018 · Expires Nov 1, 2038

    granted
  22. US 10059762

    Anti-EGFR activatable antibodies

    CytomX Therapeutics, Inc. · Granted Aug 28, 2018 · Expires Aug 23, 2038

    granted
  23. US 9889211

    Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Feb 13, 2018 · Expires Feb 8, 2038

    granted
  24. US 9737623

    Antibodies that bind activatable antibodies and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Aug 22, 2017 · Expires Aug 17, 2037

    granted